ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0272

Fostering Scientific Innovation to Impact AKI: A Roadmap from the AKI!Now Basic Science Workgroup

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Parikh, Samir M., Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
  • Agarwal, Anupam, The University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Bajwa, Amandeep, The University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee, United States
  • Kumar, Sanjeev, Cedars-Sinai Medical Center, Los Angeles, California, United States
  • Mansour, Sherry, Yale University School of Medicine, New Haven, Connecticut, United States
  • Okusa, Mark D., University of Virginia, Charlottesville, Virginia, United States
  • Cerda, Jorge, St. Peter's Health Partners, Albany, New York, United States

Group or Team Name

  • AKI!Now Basic Science Workgroup
Background

The American Society of Nephrology convened a new initiative in 2020, AKI!Now, to promote excellence in the prevention and treatment of acute kidney injury (AKI). AKI!Now’s interests are broad, spanning molecular and cell biology research through provider education and patient advocacy. Here we describe current efforts of AKI!Now’s Basic Science Workgroup to foster innovation in the prevention, diagnosis, and treatment of AKI by leveraging fundamental discoveries. Both in hospitals and the community, the incidence of AKI is high and increasing worldwide. For the individual patient, severe AKI is a life-altering event with profound future consequences. At the societal level, AKI is increasingly recognized as a major public health burden.

Methods

We propose the following goals to promote collaborative and inclusive discovery research that could translate more effectively to our patients:

Results



(1) to develop a centralized portal that provides a living resource for the research community and access to open data sources; (2) to lower entry barriers for researchers interested in AKI by developing interactive educational content; (3) to promote greater collaboration between AKI basic researchers, translational investigators, and researchers in other fields; (4) to articulate a preclinical roadmap that facilitates the development of novel interventions; and (5) to enhance communication around AKI innovation by fostering an open and vibrant community of patients, researchers, clinicians, and other stakeholders.

Conclusion

State-of-the-art medical care of AKI patients remains reactive and supportive. No targeted treatment has yet been identified to prevent this syndrome or hasten the recovery to health. Lowering barriers for new entrants and increasing opportunities for collaborations across a wide spectrum of stakeholders may help promote a culture of innovation to impact AKI.